Department of Otorhinolaryngology-Head & Neck Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Sci Rep. 2021 Apr 12;11(1):7912. doi: 10.1038/s41598-021-87297-6.
The association of thyroid cancer with statin use is controversial. This study aimed to investigate the association of previous statin use with thyroid cancer in the ≥ 40-year-old population in the Korean National Health Insurance Service-Health Screening Cohort. The 5501 patients in the thyroid cancer group were matched with the 22,004 patients in the non-thyroid cancer group for age, sex, income, and region of residence. Previous statin use during the 2 years before the diagnosis of thyroid cancer was examined. The odds ratios (ORs) with 95% confidence intervals (CIs) of previous statin use for thyroid cancer were estimated using conditional logistic regression analyses. Additionally, subgroup analyses were conducted. The thyroid cancer group showed more days of previous statin use than the non-thyroid cancer group (72.3, standard deviation [SD] = 181.2 days vs. 64.3, SD = 174.4 days, P = 0.003). Although the odds of previous statin use for thyroid cancer were high in the crude model (OR = 1.10, 95% CI 1.04-1.17, P = 0.002), they were low in the fully adjusted model (OR = 0.89, 95% CI 0.82-0.95, P = 0.001). According to age and sex subgroups, the younger (< 60 years old) male group showed lower odds for thyroid cancer according to previous statin use (adjusted OR = 0.70, 95% CI 0.55-0.88, P = 0.003), but this finding was not observed in other subgroups of older men or in any groups of women. Thyroid cancer was negatively associated with statin use in the previous 2 years in the adjusted model.
甲状腺癌与他汀类药物使用的相关性存在争议。本研究旨在探讨韩国国民健康保险服务-健康筛查队列中≥40 岁人群中他汀类药物使用与甲状腺癌之间的关系。将 5501 例甲状腺癌患者与 22004 例非甲状腺癌患者按年龄、性别、收入和居住地进行匹配。检查了甲状腺癌诊断前 2 年内的既往他汀类药物使用情况。使用条件逻辑回归分析估计了既往他汀类药物使用与甲状腺癌的比值比（OR）及其 95%置信区间（CI）。此外，还进行了亚组分析。甲状腺癌组的既往他汀类药物使用天数多于非甲状腺癌组（72.3，标准差[SD] = 181.2 天比 64.3，SD = 174.4 天，P = 0.003）。虽然在粗模型中，甲状腺癌患者使用他汀类药物的可能性较高（OR = 1.10，95%CI 1.04-1.17，P = 0.002），但在完全调整模型中，这种可能性较低（OR = 0.89，95%CI 0.82-0.95，P = 0.001）。根据年龄和性别亚组，年龄较小（<60 岁）的男性组中，根据他汀类药物使用情况，甲状腺癌的可能性较低（调整后 OR = 0.70，95%CI 0.55-0.88，P = 0.003），但在其他年龄较大的男性亚组或任何女性组中均未观察到这种情况。在调整后的模型中，甲状腺癌与前 2 年内的他汀类药物使用呈负相关。
